Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa

Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa

ObjectiveTo evaluate the efficacy of ceftazidime-avibactam (CZA) and aztreonam-avibactam (AZA) against bloodstream infections (BSIs) or lower respiratory tract infections (LRTIs) – caused by extensive drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa.MethodThe two-fold dilution m...

Full description

Bibliographic Details
Main Authors:	Yixin Kang, Lu Xie, Jiyong Yang, Junchang Cui
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Cellular and Infection Microbiology
Subjects:	extensively drug-resistant Pseudomonas aeruginosa pan drug-resistant Pseudomonas aeruginosa ceftazidime-avibactam 173 aztreonam-avibactam whole-genome sequencing
Online Access:	https://www.frontiersin.org/articles/10.3389/fcimb.2023.1023948/full

Similar Items

Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
by: María M. Montero, et al.
Published: (2021-09-01)

Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools
by: Gil Verschelden, et al.
Published: (2023-11-01)

In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula
by: Ágnes Sonnevend, et al.
Published: (2020-10-01)

Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China
by: Sun S, et al.
Published: (2022-04-01)

In vitro effectiveness of ceftazidime-avibactam in combination with aztreonam on carbapenemase-producing Enterobacterales
by: Papa-Ezdra Romina, et al.
Published: (2023-12-01)

In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany
by: Michael Kresken, et al.
Published: (2021-06-01)

Emergence of Ceftazidime- and Avibactam-Resistant Klebsiella pneumoniae Carbapenemase-Producing Pseudomonas aeruginosa in China
by: Yiwei Zhu, et al.
Published: (2021-12-01)

In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates
by: Dan Li, et al.
Published: (2023-12-01)

Resistance Genes and Molecular Epidemiology in Ceftazidime-Avibactam-Resistant Pseudomonas aeruginosa Isolates
by: Neslihan ARICI, et al.
Published: (2023-10-01)

In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019
by: Zou C, et al.
Published: (2020-10-01)

Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa
by: Yulin Zhang, et al.
Published: (2022-04-01)

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam
by: Atkin SD, et al.
Published: (2018-09-01)

In Vitro Activities of Ceftazidime–Avibactam and Aztreonam–Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates
by: Moonsuk Bae, et al.
Published: (2021-12-01)

Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection
by: Chen J, et al.
Published: (2022-02-01)

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China
by: Wei Yu, et al.
Published: (2021-11-01)

Prevalence and molecular characteristics of ceftazidime-avibactam resistance among carbapenem-resistant Pseudomonas aeruginosa clinical isolates
by: Yili Chen, et al.
Published: (2024-03-01)

In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant <i>Enterobacterales</i> Isolates from South Korea
by: Taeeun Kim, et al.
Published: (2020-12-01)

Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro
by: Qiuxia Lin, et al.
Published: (2021-02-01)

Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals
by: María Fernanda Mojica, et al.
Published: (2023-04-01)

Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients
by: Chen J, et al.
Published: (2023-04-01)

Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: A single-centre study
by: Jie Wei, et al.
Published: (2020-09-01)

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
by: Alessandro Mancuso, et al.
Published: (2023-08-01)

Resistance to aztreonam-avibactam due to a mutation of SHV-12 in Enterobacter
by: Shikai Wu, et al.
Published: (2023-06-01)

Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
by: Leilei Wang, et al.
Published: (2023-06-01)

CP-CRE/non-CP-CRE Stratification And CRE Resistance Mechanism Determination Help In Better Managing CRE Bacteremia Using Ceftazidime–Avibactam And Aztreonam–Avibactam
by: Zou H, et al.
Published: (2019-09-01)

Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope
by: Rawan Taha, et al.
Published: (2023-03-01)

Successful Treatment of Ventriculitis Caused by MDR/XDR Gram-Negative Bacillus Using Ceftazidime/Avibactam: Case Series and Literature Review
by: Zhou Q, et al.
Published: (2021-05-01)

Ceftazidime-avibactam and comparators against Pseudomonas aeruginosa isolates collected globally and in each geographical region between 2017–2020
by: Pattarachai Kiratisin, et al.
Published: (2023-09-01)

Evaluation of clinical and microbiological factors related to mortality in patients with Gram-negative bacterial infections treated with ceftazidime–avibactam: A prospective multicentric cohort study
by: Beatriz Arns, et al.
Published: (2024-03-01)

Ceftazidime-avibactam/aztreonam combination synergy against carbapenem-resistant Gram-negative isolates: In vitro study
by: Reena Rajan, et al.
Published: (2024-01-01)

The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases
by: Carola Mauri, et al.
Published: (2021-08-01)

Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015‒2020
by: Mark G. Wise, et al.
Published: (2023-05-01)

Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
by: Baharak Babouee Flury, et al.
Published: (2023-04-01)

Extensively drug-resistant Pseudomonas aeruginosa: clinical features and treatment with ceftazidime/avibactam and ceftolozane/tazobactam in a tertiary care university hospital center in Portugal – A cross-sectional and retrospective observational study
by: Diogo Mendes Pedro, et al.
Published: (2024-02-01)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i>: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
by: Marianna Meschiari, et al.
Published: (2021-10-01)

In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015–2021
by: Luis C. Torres-Castillo, et al.
Published: (2023-12-01)

In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014–2018
by: Elkin V. Lemos-Luengas, MD, PhD, et al.
Published: (2022-06-01)

Evaluation of Aztreonam and Ceftazidime/Avibactam Synergism against <i>Klebsiella pneumoniae</i> by MALDI-TOF MS
by: Camila Mörschbächer Wilhelm, et al.
Published: (2023-06-01)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
by: Zeyu Huang, et al.
Published: (2023-11-01)

Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital
by: C. Weber, et al.
Published: (2022-10-01)